Sartorius Aktiengesellschaft
Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers analytical solutions, such as biolayer interferometry systems, high-throughput screening by cytometry systems, process analytical technology and data analytics, cell selection and retrieval, live-cell imaging and analysis systems, and surface plasmon resonance systems; cell cult… Read more
Sartorius Aktiengesellschaft (SUVPF) - Net Assets
Latest net assets as of December 2025: $3.87 Billion USD
Based on the latest financial reports, Sartorius Aktiengesellschaft (SUVPF) has net assets worth $3.87 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($9.71 Billion) and total liabilities ($5.85 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $3.87 Billion |
| % of Total Assets | 39.8% |
| Annual Growth Rate | 15.74% |
| 5-Year Change | 124.73% |
| 10-Year Change | 424.68% |
| Growth Volatility | 22.09 |
Sartorius Aktiengesellschaft - Net Assets Trend (2002–2025)
This chart illustrates how Sartorius Aktiengesellschaft's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Sartorius Aktiengesellschaft (2002–2025)
The table below shows the annual net assets of Sartorius Aktiengesellschaft from 2002 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $3.87 Billion | -0.82% |
| 2024-12-31 | $3.90 Billion | +41.36% |
| 2023-12-31 | $2.76 Billion | +3.70% |
| 2022-12-31 | $2.66 Billion | +54.57% |
| 2021-12-31 | $1.72 Billion | +22.68% |
| 2020-12-31 | $1.40 Billion | +29.69% |
| 2019-12-31 | $1.08 Billion | +11.08% |
| 2018-12-31 | $973.39 Million | +20.68% |
| 2017-12-31 | $806.56 Million | +9.47% |
| 2016-12-31 | $736.80 Million | +14.28% |
| 2015-12-31 | $644.75 Million | +29.71% |
| 2014-12-31 | $497.08 Million | +10.40% |
| 2013-12-31 | $450.25 Million | +11.50% |
| 2012-12-31 | $403.82 Million | +10.33% |
| 2011-12-31 | $366.02 Million | +11.87% |
| 2010-12-31 | $327.18 Million | +2.49% |
| 2009-12-31 | $319.25 Million | -4.24% |
| 2008-12-31 | $333.38 Million | -0.21% |
| 2007-12-31 | $334.10 Million | +97.77% |
| 2006-12-31 | $168.93 Million | +13.87% |
| 2005-12-31 | $148.35 Million | +8.66% |
| 2004-12-31 | $136.53 Million | +5.89% |
| 2003-12-31 | $128.93 Million | -3.70% |
| 2002-12-31 | $133.88 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Sartorius Aktiengesellschaft's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 8605.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $2.49 Billion | 92.04% |
| Common Stock | $69.07 Million | 2.55% |
| Other Comprehensive Income | $-100.26 Million | -3.71% |
| Other Components | $246.61 Million | 9.11% |
| Total Equity | $2.71 Billion | 100.00% |
Sartorius Aktiengesellschaft Competitors by Market Cap
The table below lists competitors of Sartorius Aktiengesellschaft ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Pinnacle Financial Partners, Inc.
NASDAQ:PNFP
|
$7.40 Billion |
|
IDACORP Inc
NYSE:IDA
|
$7.41 Billion |
|
Aegon Ltd.
F:J060
|
$7.41 Billion |
|
Aegon NV
AS:AGN
|
$7.41 Billion |
|
Keyera Corp
PINK:KEYUF
|
$7.39 Billion |
|
Cytokinetics Inc
NASDAQ:CYTK
|
$7.39 Billion |
|
Powszechny Zaklad Ubezpieczen SA
PINK:PZAKY
|
$7.39 Billion |
|
Tata Motors Passenger Vehicles Limited
NSE:TMPV
|
$7.39 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sartorius Aktiengesellschaft's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,764,800,000 to 2,705,786,197, a change of -59,013,803 (-2.1%).
- Net income of 154,841,983 contributed positively to equity growth.
- Dividend payments of 50,681,010 reduced retained earnings.
- Other comprehensive income decreased equity by 409,062,433.
- Other factors increased equity by 245,887,657.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $154.84 Million | +5.72% |
| Dividends Paid | $50.68 Million | -1.87% |
| Other Comprehensive Income | $-409.06 Million | -15.12% |
| Other Changes | $245.89 Million | +9.09% |
| Total Change | $- | -2.13% |
Book Value vs Market Value Analysis
This analysis compares Sartorius Aktiengesellschaft's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.07x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 102.22x to 5.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $1.95 | $198.85 | x |
| 2003-12-31 | $1.89 | $198.85 | x |
| 2004-12-31 | $2.00 | $198.85 | x |
| 2005-12-31 | $2.18 | $198.85 | x |
| 2006-12-31 | $2.48 | $198.85 | x |
| 2007-12-31 | $4.27 | $198.85 | x |
| 2008-12-31 | $4.25 | $198.85 | x |
| 2009-12-31 | $4.00 | $198.85 | x |
| 2010-12-31 | $4.06 | $198.85 | x |
| 2011-12-31 | $4.50 | $198.85 | x |
| 2012-12-31 | $4.89 | $198.85 | x |
| 2013-12-31 | $5.39 | $198.85 | x |
| 2014-12-31 | $5.84 | $198.85 | x |
| 2015-12-31 | $7.59 | $198.85 | x |
| 2016-12-31 | $8.48 | $198.85 | x |
| 2017-12-31 | $9.03 | $198.85 | x |
| 2018-12-31 | $10.83 | $198.85 | x |
| 2019-12-31 | $11.85 | $198.85 | x |
| 2020-12-31 | $15.31 | $198.85 | x |
| 2021-12-31 | $18.42 | $198.85 | x |
| 2022-12-31 | $29.08 | $198.85 | x |
| 2023-12-31 | $30.22 | $198.85 | x |
| 2024-12-31 | $40.05 | $198.85 | x |
| 2025-12-31 | $39.19 | $198.85 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sartorius Aktiengesellschaft utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.72%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.38%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 3.59x
- Recent ROE (5.72%) is below the historical average (13.65%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 3.01% | 0.84% | 1.20x | 3.00x | $-9.28 Million |
| 2003 | 3.39% | 0.99% | 1.21x | 2.85x | $-8.51 Million |
| 2004 | 11.16% | 3.26% | 1.31x | 2.62x | $1.58 Million |
| 2005 | 14.91% | 4.57% | 1.32x | 2.47x | $7.28 Million |
| 2006 | 17.18% | 5.57% | 1.38x | 2.23x | $12.13 Million |
| 2007 | 10.35% | 5.12% | 0.75x | 2.69x | $1.01 Million |
| 2008 | 4.27% | 2.02% | 0.71x | 2.99x | $-16.61 Million |
| 2009 | 0.36% | 0.16% | 0.73x | 3.01x | $-26.28 Million |
| 2010 | 11.19% | 4.70% | 0.82x | 2.91x | $3.30 Million |
| 2011 | 13.54% | 5.67% | 0.76x | 3.14x | $10.88 Million |
| 2012 | 14.53% | 5.74% | 0.79x | 3.21x | $15.13 Million |
| 2013 | 14.26% | 5.91% | 0.76x | 3.19x | $15.66 Million |
| 2014 | 12.19% | 5.44% | 0.70x | 3.20x | $8.70 Million |
| 2015 | 24.40% | 11.33% | 0.78x | 2.78x | $74.53 Million |
| 2016 | 17.76% | 7.92% | 0.74x | 3.02x | $44.97 Million |
| 2017 | 18.57% | 8.17% | 0.61x | 3.72x | $52.95 Million |
| 2018 | 19.09% | 9.03% | 0.62x | 3.41x | $67.29 Million |
| 2019 | 19.34% | 8.58% | 0.64x | 3.51x | $75.65 Million |
| 2020 | 20.05% | 9.00% | 0.50x | 4.48x | $105.33 Million |
| 2021 | 25.30% | 9.25% | 0.61x | 4.52x | $192.87 Million |
| 2022 | 34.08% | 16.24% | 0.60x | 3.51x | $479.12 Million |
| 2023 | 9.93% | 6.04% | 0.35x | 4.72x | $-1.53 Million |
| 2024 | 3.04% | 2.48% | 0.33x | 3.65x | $-192.48 Million |
| 2025 | 5.72% | 4.38% | 0.36x | 3.59x | $-115.74 Million |
Industry Comparison
This section compares Sartorius Aktiengesellschaft's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $2,683,526,542
- Average return on equity (ROE) among peers: -32.48%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sartorius Aktiengesellschaft (SUVPF) | $3.87 Billion | 3.01% | 1.51x | $7.40 Billion |
| ANGELALIGN TECHNOLOGY INC (AGLFF) | $480.24 Million | 2.52% | 0.41x | $405.57 Million |
| Akoya Biosciences Inc (AKYA) | $-30.16 Million | 0.00% | 0.00x | $16.24 Million |
| Alcon AG (ALC) | $19.68 Billion | 1.70% | 0.48x | $37.82 Billion |
| Align Technology Inc (ALGN) | $3.85 Billion | 10.94% | 0.61x | $11.75 Billion |
| AngioDynamics Inc (ANGO) | $355.71 Million | 3.06% | 0.15x | $354.40 Million |
| Ansell Limited (ANSLF) | $386.33 Million | -0.45% | 0.87x | $2.58 Billion |
| AptarGroup Inc (ATR) | $2.07 Billion | 11.57% | 1.03x | $8.27 Billion |
| AtriCure Inc (ATRC) | $72.60 Million | -15.79% | 0.54x | $1.42 Billion |
| Avinger Inc (AVGR) | $-35.69 Million | 0.00% | 0.00x | $1.26 Million |
| Anteris Technologies Global Corp. Common Stock (AVR) | $9.03 Million | -338.35% | 0.77x | $156.14 Million |